Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma
| Autor: | Jia-Cheng Ye, Yongzheng Wang, Zhaomin Song, Wujie Wang, Yuliang Li |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Carcinoma Hepatocellular medicine.medical_treatment brachytherapy Brachytherapy Kaplan-Meier Estimate unresectable hepatocellular carcinoma lcsh:RC254-282 Iodine Radioisotopes Lesion 03 medical and health sciences Pseudoaneurysm 0302 clinical medicine iodine-125 medicine Clinical endpoint Humans Radiology Nuclear Medicine and imaging Radiometry Neoplasm Staging Aged 80 and over Porta hepatis business.industry Radiotherapy Planning Computer-Assisted Liver Neoplasms Hazard ratio Radiotherapy Dosage General Medicine lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Magnetic Resonance Imaging Confidence interval Tumor Burden Treatment Outcome 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma Disease Progression Female Radiology medicine.symptom Tomography X-Ray Computed business Radiotherapy Image-Guided |
| Zdroj: | Journal of Cancer Research and Therapeutics, Vol 15, Iss 7, Pp 1553-1560 (2019) |
| ISSN: | 0973-1482 |
| DOI: | 10.4103/jcrt.jcrt_629_19 |
| Popis: | Purpose: This study aimed to retrospectively assess the outcome of interstitial iodine-125 brachytherapy for unresectable hepatocellular carcinoma (HCC). Materials and Methods: Between February 2013 and March 2019, 57 patients with 108 unresectable HCC lesions treated with computed tomography (CT)-guided iodine-125 seed brachytherapy were retrospectively analyzed. The primary endpoint was overall survival (OS). The secondary endpoints included local tumor control and progression-free survival (PFS). Potential factors associated with OS were assessed. Results: The mean follow-up duration was 24.3 ± 15.6 months (median, 20.5 months; range, 3.9–66.8 months). The median OS time was 23.6 months (95% confidence interval [CI], 18.4–28.8 months). The 1-, 2-, and 3-year actuarial OS rates were 80.0%, 46.1%, and 24.3%, respectively. The median PFS time was 12 months (95% CI, 9.9–14.5 months). The 1- and 2-year actuarial PFS rates were 50% and 20.1%, respectively. Local progression was noted in 11 (11.3%) of 108 lesions with mean local control time of 20.5 ± 8.8 months. The 1- and 2-year local control rates were 96.5% and 88.8%, respectively. Barcelona clinic liver cancer stage and Child–Pugh score were independent risk factors affecting the prognosis (hazard ratio [HR] = 0.330 [95% CI, 0.128–0.853] and HR = 0.303 [95% CI, 0.151–0.610], respectively). Hepatic artery pseudoaneurysm was found in 1 (1.8%) patient with lesion located in the porta hepatis. No other major complications developed during follow-up. Conclusion: CT-guided iodine-125 brachytherapy may be an effective and safe alternative with promising survival and increased local control rate in unresectable HCC treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|